Intranasal soluble ACE2 improves organ histopathology and survival in k18hACE2 mice infected with SARS-CoV-2
- Alternative title
-
Intranasales lösliches ACE2 Protein verbessert Überleben und Organhistopathologie in SARS-CoV-2 infizierten k18hACE2 Mäusen
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Berlin, Medizinische Fakultät Charité - Universitätsmedizin Berlin, Dissertation, 2025
- Keyword
-
Histopathologie
Tiermodell
- Event
-
Veröffentlichung
- (where)
-
Berlin
- (who)
-
Medizinische Fakultät Charité - Universitätsmedizin Berlin
- (when)
-
2025
- Creator
- DOI
-
10.17169/refubium-45637
- URN
-
urn:nbn:de:kobv:188-refubium-45924-8
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hassler, Luise
- Medizinische Fakultät Charité - Universitätsmedizin Berlin
Time of origin
- 2025
Other Objects (12)
Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID19
Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19
Age and sex differences in soluble ACE2 may give insights for COVID-19
Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection
Coronaviruses Use ACE2 Monomers as Entry‐Receptors
Coronaviruses Use ACE2 Monomers as Entry‐Receptors
COVID-19 susceptibility: potential of ACE2 polymorphisms
Structural insight into the substrate recognition and transport mechanism of amino acid transporter complex ACE2-B0AT1 and ACE2-SIT1
ACE2/Ang-(1–7) signaling and vascular remodeling
Comparative ACE2 variation and primate COVID-19 risk
ACE2, a drug target for COVID-19 treatment?
Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2
Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID19
Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19
Age and sex differences in soluble ACE2 may give insights for COVID-19
Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection
Coronaviruses Use ACE2 Monomers as Entry‐Receptors
Coronaviruses Use ACE2 Monomers as Entry‐Receptors
COVID-19 susceptibility: potential of ACE2 polymorphisms
Structural insight into the substrate recognition and transport mechanism of amino acid transporter complex ACE2-B0AT1 and ACE2-SIT1
ACE2/Ang-(1–7) signaling and vascular remodeling
Comparative ACE2 variation and primate COVID-19 risk
ACE2, a drug target for COVID-19 treatment?
Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2
Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID19
Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19
Age and sex differences in soluble ACE2 may give insights for COVID-19
Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection
Coronaviruses Use ACE2 Monomers as Entry‐Receptors
Coronaviruses Use ACE2 Monomers as Entry‐Receptors
COVID-19 susceptibility: potential of ACE2 polymorphisms
Structural insight into the substrate recognition and transport mechanism of amino acid transporter complex ACE2-B0AT1 and ACE2-SIT1
ACE2/Ang-(1–7) signaling and vascular remodeling
Comparative ACE2 variation and primate COVID-19 risk
ACE2, a drug target for COVID-19 treatment?